PT  - JOURNAL ARTICLE
AU  - Nicole Brooks
AU  - Dodie S. Pouniotis
TI  - Immunomodulation in Endometrial Cancer
AID  - 10.1111/IGC.0b013e3181a12f7f
DP  - 2009 Apr 01
TA  - International Journal of Gynecologic Cancer
PG  - 734-740--734-740
VI  - 19
IP  - 4
4099  - http://ijgc.bmj.com/content/19/4/734-740.short
4100  - http://ijgc.bmj.com/content/19/4/734-740.full
SO  - Int J Gynecol Cancer2009 Apr 01; 19
AB  - Endometrial cancer is the most frequent gynecological cancer and the fourth most common cancer in women in the developed world. Over the last decade, immunotherapy has been the focus of intense investigation as a form of cancer treatment whereby the treatment initiates a host immune response ultimately eradicating the tumor. It has been suggested that in endometrial cancer and many other forms of cancer, immunosuppression poses a significant obstacle at inducing antitumor immunity by immunotherapy. This review will look at the different studies that have identified immunomodulation of T cells, cytokines and macrophages, and regulation of apoptotic and angiogenic factors in endometrial cancer patients that may contribute to the inefficiency of immunotherapy.